title: Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis.
abstract: Adverse effects may occur in 10.4% of patients receiving terbinafine therapy, with cutaneous reactions in 2.7%. We describe the development of psoriasis in four patients who took oral terbinafine. Two patients had plaque-type psoriasis that flared 12 and 17 days, respectively, after starting terbinafine. Another patient developed pustular-type psoriasis de novo after 27 days of terbinafine therapy. The fourth patient was a psoriatic with stable plaque disease who experienced a pustular flare after taking terbinafine for 21 days. We are aware of only one report in the literature in which a patient developed pustular psoriasis de novo after 5 days of terbinafine therapy. In all patients the psoriasis cleared or lessened after discontinuation of terbinafine and institution of antipsoriatic therapy.
authors.affiliation: Department of Medicine, Sunnybrook Health Science Center, Toronto, Canada.
authors.forename: A K
authors.initials: AK
authors.lastname: Gupta
authors.forename: R G
authors.initials: RG
authors.lastname: Sibbald
authors.forename: S R
authors.initials: SR
authors.lastname: Knowles
authors.forename: C W
authors.initials: CW
authors.lastname: Lynde
authors.forename: N H
authors.initials: NH
authors.lastname: Shear
mesh_terms: D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000009:adverse effects*; D011565:Psoriasis / Q000139:chemically induced* / Q000473:pathology; D000077291:Terbinafine
chemical_list: D000935:Antifungal Agents; D009281:Naphthalenes; D000077291:Terbinafine